Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma
BACKGROUND. Growth factor overexpression, including epidermal growth factor receptor
(EGFR) expression, is common in hepatocellular cancers. Erlotinib is a receptor tyrosine …
(EGFR) expression, is common in hepatocellular cancers. Erlotinib is a receptor tyrosine …
Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small …
FA Greco, P Bonomi, J Crawford, K Kelly, Y Oh… - Lung cancer, 2008 - Elsevier
BACKGROUND: Preclinical pharmacological properties of mapatumumab (agonistic human
monoclonal antibody to TRAIL-R1) suggest that this antibody reduces cell viability, induces …
monoclonal antibody to TRAIL-R1) suggest that this antibody reduces cell viability, induces …
Non-cancer mortality among people diagnosed with cancer (Australia)
Objective To investigate whether people diagnosed with cancer have an increased risk of
death from non-cancer causes compared to the general population. Methods The non …
death from non-cancer causes compared to the general population. Methods The non …
Phase II randomized study of the IGF-1R pathway modulator AXL1717 compared to docetaxel in patients with previously treated, locally advanced or metastatic non …
M Bergqvist, G Holgersson, I Bondarenko… - Acta …, 2017 - Taylor & Francis
Background: The primary objective of this study was to compare the progression-free
survival (PFS) at 12 weeks between patients treated with IGF-1R pathway modulator …
survival (PFS) at 12 weeks between patients treated with IGF-1R pathway modulator …
[HTML][HTML] The prognostic value of pre-treatment leukocytosis in patients with previously treated, stage IIIB/IV non-small cell lung Cancer treated with the IGF-1R pathway …
G Holgersson, M Bergqvist, J Nilsson… - Asian Pacific journal …, 2017 - ncbi.nlm.nih.gov
Background: The aim of the present study was to investigate any prognostic value of pre-
treatment anemia, leukocytosis and thrombocytosis in patients with advanced pretreated …
treatment anemia, leukocytosis and thrombocytosis in patients with advanced pretreated …
[PDF][PDF] 吉非替尼治疗晚期非小细胞肺癌的临床研究
冯仲珉， 刘艳娥， 孙利敏， 孙鹏， 孙艳 - 2007 - journal.dmu.edu.cn
[目的] 观察吉非替尼(Gefitinib) 治疗含钩类化疗失败的晚期非小细胞肺癌的疗效及毒副作用.[
方法] 对76 例含钧类化疗失败的晚期非小细胞肺癌患者给予吉非替尼250 mgld 口服治疗 …
方法] 对76 例含钧类化疗失败的晚期非小细胞肺癌患者给予吉非替尼250 mgld 口服治疗 …
[HTML][HTML] Phase II trial of sequential gefitinib after minor response or partial response to chemotherapy in Chinese patients with advanced non-small-cell lung cancer
JM Xu, Y Han, YM Li, CH Zhao, Y Wang, A Paradiso - BMC cancer, 2006 - Springer
Background Basic research of gefitinib (Iressa, ZD1839) has demonstrated the combination
effects of gefitinib and chemotherapy were sequence-dependent. To evaluate the efficacy of …
effects of gefitinib and chemotherapy were sequence-dependent. To evaluate the efficacy of …
EGFR/HER2/HER3 expression in tumour and gefitinib treatment in Chinese patients with advanced non-small cell lung cancer
J Xu, E Gao, Y Han, Y Zhang, S Li, X Liu, Z Li… - The Chinese-German …, 2008 - Springer
Objective Biological markers performable in routine practice and able to predict the clinical
outcome of advanced non-small cell lung cancer (NSCLC) treated with gefitinib are urgently …
outcome of advanced non-small cell lung cancer (NSCLC) treated with gefitinib are urgently …